Skip to content
Contact Us
AdobeStock_171759632 AdobeStock_171759632

Global Immune Monitoring Solutions

Industry-leading array of comprehensive immune monitoring solutions

Precision provides comprehensive immune monitoring services, from the development of customized assays for early clinical studies to managing the logistical and immune monitoring testing needs of global, registrational trials. We leverage multiple technology platforms on a global scale, including proprietary innovations like Epiontis ID®.

Unraveling the complexities of immunity: tailored solutions for detailed insights

  • Explore

    Flow Cytometry

    Standard and spectral flow cytometry, on both research-grade and CLIA-validated instruments
    Explore
  • Explore

    Epiontis ID® Epigenetic Cell Profiling

    Precision’s proprietary immune monitoring technology which delivers robust, repeatable, and cost-effective immune cell phenotyping on any sample type
    Explore
  • Explore

    Cytokine Profiling & Proteomics

    Customized assays to detect cytokines or proteins of interest utilizing ELISA, Luminex, MSD, SIMOA, and Western Blotting

    Explore
  • Explore

    ELISpot and Fluorospot

    ELISpot and FluoroSpot - including custom assays in support of gene therapy immunogenicity - from preclinical through clinical development

    Explore
  • Explore

    Cell-Based Assays

    Developing and qualifying 2D and 3D human in vitro cell-based models using a broad range of human primary cell types, with analysis enabling a variety of endpoints
    Explore
  • Explore
    companion-diagnostic

    Gene Expression Profiling of Biopsies

    Understand target expression, adaptive and innate immune responses at the gene expression level. Technologies we use for gene expression profiling include NanoString, Illumina RNA-seq, ddPCR, and qPCR.

    Explore

Efficient sample management logistics enable global immune monitoring services

Precision’s immune monitoring services are strengthened by a global logistics network, designed to safeguard sample integrity and maximize data reliability.

Clinical Reach

Global clinical sample and PBMC processing

  • Global PBMC processing in 24-hours or less
  • Regular competency assessment and monitoring to ensure site-to-site and lab-to-lab data comparability
  • Long- and short-term storage at optimal temperatures

Clinical sample logistics and biostorage

We have a 100,000 sq. ft. biorepository, which includes our 140,000 sq. ft. campus in Frederick, Maryland, and our global logistics and biobanking facilities in Berlin, Germany. This extensive network was the first to receive CAP certification. Currently, we are responsible for the storage of >20 million biospecimens under controlled conditions. We can accommodate any type of fluid or solid biological specimen at controlled ambient temperatures, +4℃, -20℃, -80℃, or in liquid nitrogen vapor.

The biorepository includes numerous security and safety features:

  • Redundant back-up systems, dedicated back-up units
  • Around-the-clock automated temperature monitoring
  • In-house HVAC technicians, specializing in cascade refrigeration

Unlocking potential: flow cytometry for breakthrough research

Precision for Medicine offers a suite of flow cytometry services tailored to the intricate demands of modern scientific research and therapeutic development

Brochure

Multiparametric Flow Cytometry

Download Brochure
Multiparametric Flow Cytometry

Epiontis ID® - Optimized Immune Profiling

Within our suite of immune monitoring services, Epiontis ID® proprietary technology stands out by offering an epigenetic approach to cell profiling. See how it works.

Explore

Related resources

Blog - Ut libero urna, finibus sed tortor nec, fringilla blandit est

Nullam fermentum, massa vel lacinia pellentesque, nulla erat condimentum ipsum, ac blandit sapien neque sed sem. Quisque bibendum semper erat, nec luctus ligula.

Visit blog
Read: 2025 Biotech Economics: CROs, Advanced Therapies & Trends in Funding 2025 Biotech Economics: CROs, Advanced Therapies & Trends in Funding

Clinical Trials - Early Phase Research

2025 Biotech Economics: CROs, Advanced Therapies & Trends in Funding

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1741014116242, hs_published_at=1741014119284, description=Rob Maiale is a marketing strategist and creative technologist known for shaping content strategies that drive engagement, influence, and business impact. With more than 15 years of experience spanning clinical research, patient education, pharma, and diagnostics, he specializes in turning expert insights into market-shaping narratives. At Precision, Rob leads innovative storytelling initiatives that connect cutting-edge science with the right audiences—leveraging AI, emerging technologies, and deep industry expertise to keep content ahead of the curve., avatar=Image{width=400,height=400,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Rob%20Maiale.jpg',altText='Rob Maiale',fileId=184765575245}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1741014119343, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, job=, slug=rob-maiale, email=, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Rob Maiale avatar

    Rob Maiale
Discover
Read: FDA's Project Optimus: What Pharma and Biotech Need to Know FDA's Project Optimus: What Pharma and Biotech Need to Know

Clinical Trials - Regulatory

FDA's Project Optimus: What Pharma and Biotech Need to Know

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=167363064857, hs_child_table_id=0, hs_updated_at=1719905898183, hs_published_at=1741014119284, description=Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors., avatar=Image{width=553,height=580,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Harpreet-Singh2.png',altText='Harpreet-Singh2',fileId=171747124346}, linkedin=https://www.linkedin.com/in/harpreetsinghmd/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Singh, MD, hs_initial_published_at=1715692570942, hs_created_by_user_id=2737751, hs_created_at=1715692477118, hs_is_edited=false, hs_deleted_at=0, name=Harpreet, job=Chief Medical Officer, slug=harpreet-singh, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Harpreet Singh, MD avatar

    Harpreet Singh, MD
Discover
Read: Case Study: Concurrent Phase 1 Solid Tumor Drug Development Successes Case Study: Concurrent Phase 1 Solid Tumor Drug Development Successes

Case Study: Concurrent Phase 1 Solid Tumor Drug Development Successes

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=185838258545, hs_child_table_id=0, hs_updated_at=1738849388884, hs_published_at=1741014119284, description=Anna Rodecki is a results driven leader with 24 years of experience in clinical research across the pharmaceutical, device, and biotech industries. She has played a pivotal role in shaping clinical development plans on both Sponsor and CRO, successfully supporting First- In-Human (FIH) – Phase IV trials successfully across various therapeutics areas. Anan thrives on building strong, collaborative teams fostering innovation. Her expertise spans strategic planning, risk management, inspection readiness and cross-functional leadership – always with a focus on improving patient outcomes and advancing the future of medicine., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Anna%20Rodecki.png',altText='Anna Rodecki',fileId=185842773784}, lastname=Rodecki, hs_initial_published_at=1738849393727, hs_created_by_user_id=26433386, hs_created_at=1738849349748, hs_is_edited=false, hs_deleted_at=0, name=Anna, job=Director, Project Management, slug=anna-rodecki, hs_updated_by_user_id=26433386}, second={hs_id=159488778891, hs_child_table_id=0, hs_updated_at=1709645745122, hs_published_at=1741014119284, description=Kurt Preugschat has over 11 years of statistical experience from Phase I to Phase IV clinical trials. He is a lead statistician, providing statistical support and oversight for numerous clinical trials associated with new drug applications (NDA), supplemental new drug applications (sNDA), and medical devices. His expertise includes the development of study designs to meet complex clinical questions and the measurement of desired outcomes. In addition, Kurt has extensive experience generating statistical analyses and creating complex SAS programs and macros used by study team., avatar=Image{width=150,height=150,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/kurt-preugschat.webp',altText='',fileId=null}, linkedin=https://www.linkedin.com/in/kurt-preugschat-97298923a, hs_name=, hs_path=, lastname=Preugschat, hs_initial_published_at=1716136551646, hs_created_at=1709645745122, hs_is_edited=false, hs_deleted_at=0, name=Kurt, job=, slug=kurt-preugschat, email=, hs_updated_by_user_id=26433386}, third={}})
  • Anna R. avatar

    Anna R.
  • Kurt P. avatar

    Kurt P.
Discover